Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Abbott
- Study ID
- NCT00049751
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Adalimumab — DRUG
Study Details
The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).
Key Dates
- Start date
- Sep 30, 2002
- Status verified
- Aug 2006
Study Design
- Enrollment
- 3,000 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Change in disease activity score at visit week 12 as compared to baseline
Locations (54)
Find similar trials in Mobile, AL
By condition
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina
- Rheumatoid Arthritis Patients at Risk for Interstitial Lung DiseaseRecruiting · University of Colorado, Denver · Aurora, Colorado